MCID: END002
MIFTS: 42

Endometrioid Ovary Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Endometrioid Ovary Carcinoma

MalaCards integrated aliases for Endometrioid Ovary Carcinoma:

Name: Endometrioid Ovary Carcinoma 12 15
Endometrioid Carcinoma of Ovary 12 60
Ovarian Endometrioid Carcinoma 12 17
Endometrioid Carcinoma Ovary 12 74
Malignant Ovarian Endometrioid Tumor 74
Ovarian Endometrioid Tumor 74

Characteristics:

Orphanet epidemiological data:

60
endometrioid carcinoma of ovary
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Korea, Republic of),1-9/1000000 (Europe); Age of onset: Adult,Elderly; Age of death: adult,elderly;

Classifications:



External Ids:

Disease Ontology 12 DOID:5828
NCIt 51 C7979
ICD10 via Orphanet 35 C56
UMLS via Orphanet 75 C0346163
Orphanet 60 ORPHA454723

Summaries for Endometrioid Ovary Carcinoma

Disease Ontology : 12 An ovary adenocarcinoma that has material basis in endometrial tissue.

MalaCards based summary : Endometrioid Ovary Carcinoma, also known as endometrioid carcinoma of ovary, is related to ovarian clear cell carcinoma and ovarian serous carcinoma. An important gene associated with Endometrioid Ovary Carcinoma is SERPINB11 (Serpin Family B Member 11 (Gene/Pseudogene)), and among its related pathways/superpathways are Downstream signaling events of B Cell Receptor (BCR) and Mitotic G1-G1/S phases. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, liver and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Endometrioid Ovary Carcinoma

Graphical network of the top 20 diseases related to Endometrioid Ovary Carcinoma:



Diseases related to Endometrioid Ovary Carcinoma

Symptoms & Phenotypes for Endometrioid Ovary Carcinoma

GenomeRNAi Phenotypes related to Endometrioid Ovary Carcinoma according to GeneCards Suite gene sharing:

27 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.66 ARID1A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.66 POLE
3 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.66 PTEN
4 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.66 PTEN
5 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.66 PTEN
6 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.66 ARID1A POLE PTEN
7 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.66 ARID1A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.66 ARID1A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.66 ARID1A
10 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.66 POLE
11 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.66 POLE
12 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.66 PTEN
13 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.66 POLE
14 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.66 PTEN
15 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.66 ARID1A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.66 POLE PTEN
17 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.66 ARID1A
18 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.66 POLE
19 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.66 PTEN
20 Apoptosis resistance GR00093-A-0 9.13 PPP2R1A PPP2R1B PTEN

MGI Mouse Phenotypes related to Endometrioid Ovary Carcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.92 ARID1A POLE PPP2R1A PTEN

Drugs & Therapeutics for Endometrioid Ovary Carcinoma

Drugs for Endometrioid Ovary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
3
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 23214-92-8 31703
4
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
5
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
6
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 1 119413-54-6, 123948-87-8 60700
7
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
9
Olaparib Approved Phase 2, Phase 3,Phase 3,Phase 1 763113-22-0 23725625
10
Gemcitabine Approved Phase 2, Phase 3,Phase 3 95058-81-4 60750
11
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
12
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
13
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 59-30-3 6037
15
Doxil Approved June 1999 Phase 2, Phase 3,Phase 3,Phase 1 31703
16 Paclitaxel poliglumex Experimental, Investigational Phase 3,Phase 1 263351-82-2
17
Maleic acid Experimental, Investigational Phase 2, Phase 3,Phase 3,Phase 1 110-17-8, 110-16-7 444972
18
Cediranib Investigational Phase 2, Phase 3,Phase 3,Phase 1 288383-20-0 9933475
19 Antimitotic Agents Phase 3,Phase 2,Phase 1
20 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
21 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
22 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
23 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3,Phase 1
24 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
25 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3,Phase 1
26 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 3,Phase 2,Phase 1
28 Immunoglobulins Phase 3,Phase 2,Phase 1
29 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
30 Immunoglobulin G Phase 3,Phase 2,Phase 1
31 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
32 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
33 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
34 Antibodies Phase 3,Phase 2,Phase 1
35 Mitogens Phase 3,Phase 2,Phase 1
36 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
37 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
38 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
39 topoisomerase I inhibitors Phase 2, Phase 3,Phase 1
40 Antirheumatic Agents Phase 3,Phase 2,Phase 1
41 Peripheral Nervous System Agents Phase 3,Phase 1,Not Applicable
42 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
43 Alkylating Agents Phase 3,Phase 2,Phase 1
44 Analgesics Phase 3,Phase 1
45 Micronutrients Phase 3,Not Applicable
46 Carotenoids Phase 3
47 Trace Elements Phase 3,Not Applicable
48 Antimetabolites Phase 3,Phase 2
49 Antimetabolites, Antineoplastic Phase 3,Phase 2
50 Antiviral Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 82)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
3 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
4 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
5 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
6 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
7 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
8 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
9 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
10 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
11 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
12 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
13 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
14 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
15 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
16 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
17 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
18 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Unknown status NCT02283658 Phase 2 Everolimus;Letrozole
19 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
20 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
21 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
22 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
23 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
24 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
25 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
26 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
27 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers Completed NCT00002538 Phase 2
28 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
29 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
30 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
31 Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03587311 Phase 2 Paclitaxel
32 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
33 Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
34 Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2 metformin hydrochloride;placebo;Chemotherapy
35 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib Phosphate
36 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
37 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02853318 Phase 2 Cyclophosphamide
38 Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02923739 Phase 2 Paclitaxel
39 Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting NCT01116648 Phase 1, Phase 2 Cediranib Maleate;Olaparib
40 First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Active, not recruiting NCT01097746 Phase 2 Carboplatin;Paclitaxel
41 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
42 Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Not yet recruiting NCT03924245 Phase 1, Phase 2 Entinostat;Olaparib
43 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer Terminated NCT00004221 Phase 2 Carboplatin;Cyclophosphamide;Paclitaxel;Topotecan Hydrochloride
44 Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
45 Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer Terminated NCT00354601 Phase 2 capecitabine;docetaxel
46 EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01489371 Phase 1 Pegylated Liposomal Doxorubicin Hydrochloride
47 Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT01459380 Phase 1 Carboplatin;Pegylated Liposomal Doxorubicin Hydrochloride;Veliparib
48 TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
49 Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer Completed NCT00357448 Phase 1
50 Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer Completed NCT00002913 Phase 1 paclitaxel;cisplatin;topotecan hydrochloride

Search NIH Clinical Center for Endometrioid Ovary Carcinoma

Genetic Tests for Endometrioid Ovary Carcinoma

Anatomical Context for Endometrioid Ovary Carcinoma

MalaCards organs/tissues related to Endometrioid Ovary Carcinoma:

42
Ovary, Liver, Bone, Brain, Endothelial, Bone Marrow

Publications for Endometrioid Ovary Carcinoma

Articles related to Endometrioid Ovary Carcinoma:

(show all 14)
# Title Authors Year
1
Nuclear β-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome. ( 30326146 )
2019
2
Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups. ( 28776572 )
2017
3
Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas. ( 26799366 )
2016
4
Ovarian endometrioid carcinoma with yolk sac tumor component in a postmenopausal woman. ( 29943939 )
2016
5
Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. ( 26166557 )
2015
6
A rare case of synchronous right ovarian clear cell carcinoma and an incidental left ovarian endometrioid carcinoma with immunohistochemical study. ( 24970988 )
2014
7
Frequent POLE1 p.S297F mutation in Chinese patients with ovarian endometrioid carcinoma. ( 24472300 )
2014
8
Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. ( 19967725 )
2010
9
Re: Madore et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol 2010;220:392-400. ( 20572050 )
2010
10
Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma. ( 20003326 )
2009
11
Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. ( 17952116 )
2008
12
Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma. ( 14559989 )
2003
13
Uterine atypical polypoid adenomyoma and ovarian endometrioid carcinoma: metastatic disease or dual primaries? ( 7883432 )
1995
14
A case of ovarian endometrioid carcinoma and malignant transformation of adenomyosis uteri. ( 7310201 )
1981

Variations for Endometrioid Ovary Carcinoma

Cosmic variations for Endometrioid Ovary Carcinoma:

9 (show top 50) (show all 254)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM43878 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.427G>A p.V143M 17:7675185-7675185 0
2 COSM44837 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.556G>C p.D186H 17:7675056-7675056 0
3 COSM44935 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.724T>A p.C242S 17:7674239-7674239 0
4 COSM6906 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.672+1G>A p.? 17:7674858-7674858 0
5 COSM10808 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.488A>G p.Y163C 17:7675124-7675124 0
6 COSM11089 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.584T>C p.I195T 17:7674947-7674947 0
7 COSM10758 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
8 COSM10648 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.524G>A p.R175H 17:7675088-7675088 0
9 COSM43568 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.772G>T p.E258* 17:7674191-7674191 0
10 COSM10654 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.637C>T p.R213* 17:7674894-7674894 0
11 COSM46278 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.950A>G p.Q317R 17:7673578-7673578 0
12 COSM44321 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.712T>C p.C238R 17:7674251-7674251 0
13 COSM11582 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.395A>G p.K132R 17:7675217-7675217 0
14 COSM44890 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.770T>G p.L257R 17:7674193-7674193 0
15 COSM43650 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.638G>T p.R213L 17:7674893-7674893 0
16 COSM10742 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.578A>G p.H193R 17:7674953-7674953 0
17 COSM11501 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.823T>G p.C275G 17:7673797-7673797 0
18 COSM10812 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.722C>T p.S241F 17:7674241-7674241 0
19 COSM11063 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.711G>T p.M237I 17:7674252-7674252 0
20 COSM6932 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.733G>A p.G245S 17:7674230-7674230 0
21 COSM44171 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.840A>T p.R280S 17:7673780-7673780 0
22 COSM10733 TP53 ovary,NS,carcinoma,undifferentiated carcinoma c.574C>T p.Q192* 17:7674957-7674957 0
23 COSM11224 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.394A>C p.K132Q 17:7675218-7675218 0
24 COSM10659 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.817C>T p.R273C 17:7673803-7673803 0
25 COSM44413 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.484A>G p.I162V 17:7675128-7675128 0
26 COSM43651 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.763A>T p.I255F 17:7674200-7674200 0
27 COSM10660 TP53 ovary,NS,carcinoma,undifferentiated carcinoma c.818G>A p.R273H 17:7673802-7673802 0
28 COSM43947 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.614A>G p.Y205C 17:7674917-7674917 0
29 COSM11552 TP53 ovary,NS,carcinoma,undifferentiated carcinoma c.775G>T p.D259Y 17:7674188-7674188 0
30 COSM44204 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.423C>G p.C141W 17:7675189-7675189 0
31 COSM10995 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.580C>T p.L194F 17:7674951-7674951 0
32 COSM10943 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.841G>C p.D281H 17:7673779-7673779 0
33 COSM10731 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.707A>G p.Y236C 17:7674256-7674256 0
34 COSM10646 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.725G>A p.C242Y 17:7674238-7674238 0
35 COSM43571 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.782+1G>A p.? 17:7674180-7674180 0
36 COSM10779 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.818G>T p.R273L 17:7673802-7673802 0
37 COSM43920 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.680C>T p.S227F 17:7674283-7674283 0
38 COSM10810 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.725G>T p.C242F 17:7674238-7674238 0
39 COSM43837 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.843C>G p.D281E 17:7673777-7673777 0
40 COSM44226 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.380C>T p.S127F 17:7675232-7675232 0
41 COSM11059 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.713G>A p.C238Y 17:7674250-7674250 0
42 COSM10701 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.824G>T p.C275F 17:7673796-7673796 0
43 COSM46397 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.375+2T>A p.? 17:7675992-7675992 0
44 COSM44877 TP53 ovary,NS,carcinoma,undifferentiated carcinoma c.584T>A p.I195N 17:7674947-7674947 0
45 COSM10656 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.742C>T p.R248W 17:7674221-7674221 0
46 COSM45672 TP53 ovary,NS,carcinoma,undifferentiated carcinoma c.376-2A>G p.? 17:7675238-7675238 0
47 COSM46475 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.945T>G p.S315S 17:7673583-7673583 0
48 COSM11392 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.800G>C p.R267P 17:7673820-7673820 0
49 COSM46166 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.872A>T p.K291M 17:7673748-7673748 0
50 COSM10774 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.960G>C p.K320N 17:7673568-7673568 0

Expression for Endometrioid Ovary Carcinoma

Search GEO for disease gene expression data for Endometrioid Ovary Carcinoma.

Pathways for Endometrioid Ovary Carcinoma

Pathways related to Endometrioid Ovary Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.31 PPP2R1A PPP2R1B PTEN
2
Show member pathways
12.02 POLE PPP2R1A PPP2R1B
3
Show member pathways
11.55 PPP2R1A PPP2R1B
4 11.51 PPP2R1A PPP2R1B
5
Show member pathways
11.5 PPP2R1A PPP2R1B
6 11.5 PPP2R1A PPP2R1B
7
Show member pathways
11.5 POLE PPP2R1A PPP2R1B
8
Show member pathways
11.37 PPP2R1A PPP2R1B
9 11.33 PPP2R1A PPP2R1B
10 11.28 ARID1A PTEN
11
Show member pathways
11.25 PPP2R1A PPP2R1B
12 11.18 PPP2R1A PPP2R1B
13 11.09 PPP2R1A PPP2R1B
14 10.87 PPP2R1A PPP2R1B PTEN
15 10.81 PPP2R1A PPP2R1B
16
Show member pathways
10.7 PPP2R1A PPP2R1B

GO Terms for Endometrioid Ovary Carcinoma

Cellular components related to Endometrioid Ovary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase type 2A complex GO:0000159 8.62 PPP2R1A PPP2R1B

Biological processes related to Endometrioid Ovary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to organic substance GO:0010033 9.32 PPP2R1A PTEN
2 regulation of phosphoprotein phosphatase activity GO:0043666 9.26 PPP2R1A PPP2R1B
3 embryo implantation GO:0007566 9.16 ARID1A EMP2
4 protein dephosphorylation GO:0006470 9.13 PPP2R1A PPP2R1B PTEN
5 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 8.62 PPP2R1A PPP2R1B

Molecular functions related to Endometrioid Ovary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase regulator activity GO:0019888 8.96 PPP2R1A PPP2R1B
2 protein serine/threonine phosphatase activity GO:0004722 8.8 PPP2R1A PPP2R1B PTEN

Sources for Endometrioid Ovary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....